Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine.
O'Shaughnessy J, Koeppen H, Xiao Y, Lackner MR, Paul D, Stokoe C, Pippen J Jr, Krekow L, Holmes FA, Vukelja S, Lindquist D, Sedlacek S, Rivera R, Brooks R, McIntyre K, Brownstein C, Hoersch S, Blum JL, Jones S.
O'Shaughnessy J, et al. Among authors: vukelja s.
Clin Cancer Res. 2015 Oct 1;21(19):4305-11. doi: 10.1158/1078-0432.CCR-15-0636. Epub 2015 Jun 3.
Clin Cancer Res. 2015.
PMID: 26041745
Clinical Trial.